INTERCEPTION, France Inter, dimanche 7 avril 2019 par Philippe Bardonnaud , Vanessa Descouraux , Géraldine Hallot Cannabis thérapeutique : les promesses de l'herbe https://www.franceinter.fr/emissions/interception/interception-07-avril-2019 Une excellente émission, sur le cannabis thérapeutique, essentiellement en Israël, ou il est question du "grand retard français" (et une interview de notre confrère Nicolas AUTHIER) à écouter absolument
Lire la suiteInterview avec Yann Bisiou : l’amende cannabis effective mais pour l’instant pas applicable Contraventionnalisation du cannabis en France 26 mars 2019 Camille Lezaun En janvier, l’Assemblée Nationale approuvait le projet de loi de réforme de la justice dont l’article 58 consacre la contraventionalisation du délit d’usage de stupéfiants. L’ensemble du projet a toutefois fait l’objet d’une saisine du Conseil Constitutionnel par des parlementaires, suspendant alors la promulgation de la loi. Le Conseil a rendu son avis la semaine dernière en rejetant tous les griefs opposés à l’article 58. En d’autres termes, ça y est, « l’amende Poulliat » (du nom de son créateur) est [...]
Lire la suiteMédicaments pour le traitement de la dépendance au cannabis Bibliothèque COCHRANE, 28 janvier 2019 Nielsen S, Gowing L, Sabioni P, Le Foll B https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008940.pub3/full/fr#CD008940-abs-0002 Contexte L'usage de cannabis est relativement courant et répandu mondialement. Dans la plupart des régions du monde, les usagers de cannabis sont en demande croissante de traitements. La tendance à la dépénalisation ou à la légalisation de l'usage du cannabis dans certains pays va probablement faire perdurer cette tendance. Actuellement, il n'existe pas de traitements spécifiques pour la consommation de cannabis. Cette revue visait à évaluer l'efficacité et l'innocuité des médicaments pour le traitement de la dépendance au cannabis. Date de la [...]
Lire la suiteTranslational Investigation of the Therapeutic Potential of Cannabidiol (CBD) : Toward a New Age José A. Crippa, Francisco S. Guimaraes, Alline C. Campos, Antonio W. Zuardi Frontiers in Immunology, 21 september 2018. https://doi.org/10.3389/fimmu.2018.02009 Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry. Methods: A non-systematic search was performed for studies dealing with therapeutic applications of CBD, especially performed by Brazilian researchers. Results: CBD was shown [...]
Lire la suiteThe Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder Yann Chye, Erynn Christensen, Nadia Solowij, and Murat Yücel Frontiers in Psychiatry, 19 February 2019, doi: 10.3389/fpsyt.2019.00063 Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol [...]
Lire la suiteEndocannabinoid Signaling in Autism Bhismadev Chakrabarti, Antonio Persico, Natalia Battista, Mauro Maccarrone Neurotherapeutics, 2015, Volume 12, Issue 4, 837-847. DOI 10.1007/s13311-015-0371-9 Abstract Autism spectrum disorder (ASD) is a complex behavioral condition with onset during early childhood and a lifelong course in the vast majority of cases. To date, no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a clinical diagnosis of ASD. However, these medical procedures are often implemented in order to screen for syndromic forms of the disorder (i.e., autism comorbid with known medical conditions). In the last 25 years a good deal of information has been accumulated on the main components of [...]
Lire la suiteAutism Spectrum Disorder and Cannabidiol : Have We Seen This Movie Before? Carlos A. Salgado, and Daniel Castellanos, Glob Pediatr Health. 2018; 5: 2333794X18815412 doi: 10.1177/2333794X18815412 Received July 5, 2018. Received revised October 9, 2018. Accepted for publication October 23, 2018. Recently, the use of marijuana and cannabidiol (CBD) in children with autism spectrum disorder (ASD) has received increasing attention in the media with articles sensationally titled “Marijuana may be a miracle treatment for children with autism.” An absence of empirical data appears to have resulted in a growing body of anecdotal evidence espousing the benefits of CBD for children with ASD. Some reports describe the [...]
Lire la suiteCannabinoids for Behavioral Problems in Children With ASD (CBA) ClinicalTrials.gov Identifier : NCT02956226 Recruitment Status : Completed First Posted : November 7, 2016 Last Update Posted : December 27, 2018 https://clinicaltrials.gov/ct2/show/NCT02956226?term=cannabidiol&cond=Autism+Spectrum+Disorder Sponsor : Shaare Zedek Medical Center Information provided by (Responsible Party) : Dr. Adi Aran, Shaare Zedek Medical Center Study Description Brief Summary : This study aims to assess the safety, tolerability and efficacy of cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio, BOL Pharma, Israel] for behavioral problems in children and youth with ASD. Condition or disease Intervention/treatment Phase Autistic Disorder Drug: Cannabinoids - 99% pure cannabinoids mixDrug: PlaceboDrug: Cannabinoids - whole plant extract Study Design Study [...]
Lire la suiteCannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) ClinicalTrials.gov Identifier : NCT03202303 Recruitment Status : Not yet recruiting First Posted : June 28, 2017 Last Update Posted : April 2, 2019 https://clinicaltrials.gov/ct2/show/NCT03202303?term=cannabinoids&cond=Autism+Spectrum+Disorder&rank=2 Sponsor : Eric Hollander Collaborators : United States Department of Defense, GW Pharmaceuticals Information provided by (Responsible Party) : Eric Hollander, Montefiore Medical Center, USA Study Design Study Type : Interventional (Clinical Trial) Estimated Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Phase 2, 12-week double-blind, randomized, placebo-controlled trial Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking Description: Double-Blind Primary Purpose: Treatment Official Title: Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) Estimated Study Start Date : June 2019 Estimated [...]
Lire la suiteA cannabis reader : global issues and local experiences. Perspectives on cannabis controversies, treatment and regulation in Europe EMCDDA MONOGRAPHS, 8 Volume 1 Editors : Sharon Rödner Sznitman, Börje Olsson, Robin Room European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 2008 — 392 pp. Contents Introduction Foreword : Wolfgang Götz Overview of Volume 1 : Sharon Rödner Sznitman and Börje Olsson Part I : Cannabis in the past Chapter 1 : Cannabis as medicine in Europe in the 19th century : Manfred Fankhauser Chapter 2 : The re-emergence of the therapeutic use of cannabis products : recent developments and future prospects : John Witton Chapter 3 : The pharmacology of cannabis: [...]
Lire la suite